These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 21945469)
1. In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET. Fischer K; Sossi V; von Ameln-Mayerhofer A; Reischl G; Pichler BJ Neuroimage; 2012 Feb; 59(3):2413-22. PubMed ID: 21945469 [TBL] [Abstract][Full Text] [Related]
2. In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET. Sossi V; Dinelle K; Jivan S; Fischer K; Holden JE; Doudet D J Nucl Med; 2012 May; 53(5):813-22. PubMed ID: 22492730 [TBL] [Abstract][Full Text] [Related]
3. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study. Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534 [TBL] [Abstract][Full Text] [Related]
4. In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats. Inaji M; Yoshizaki T; Okauchi T; Maeda J; Nagai Y; Nariai T; Ohno K; Ando K; Okano H; Obayashi S; Suhara T Cell Transplant; 2005; 14(9):655-63. PubMed ID: 16405076 [TBL] [Abstract][Full Text] [Related]
5. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Inaji M; Okauchi T; Ando K; Maeda J; Nagai Y; Yoshizaki T; Okano H; Nariai T; Ohno K; Obayashi S; Higuchi M; Suhara T Brain Res; 2005 Dec; 1064(1-2):136-45. PubMed ID: 16298352 [TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374 [TBL] [Abstract][Full Text] [Related]
7. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography. Acton PD; Choi SR; Plössl K; Kung HF Eur J Nucl Med Mol Imaging; 2002 May; 29(5):691-8. PubMed ID: 11976810 [TBL] [Abstract][Full Text] [Related]
8. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Nikolaus S; Larisch R; Vosberg H; Beu M; Wirrwar A; Antke C; Kley K; Silva MA; Huston JP; Müller HW Rev Neurosci; 2011; 22(6):625-45. PubMed ID: 22103308 [TBL] [Abstract][Full Text] [Related]
10. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972 [TBL] [Abstract][Full Text] [Related]
11. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. Hirvonen J; Johansson J; Teräs M; Oikonen V; Lumme V; Virsu P; Roivainen A; Någren K; Halldin C; Farde L; Hietala J J Cereb Blood Flow Metab; 2008 May; 28(5):1059-69. PubMed ID: 18183028 [TBL] [Abstract][Full Text] [Related]
12. Application of feedback-controlled bolus plus infusion (FC-B/I) method for quantitative PET imaging of dopamine transporters with [(18)F]β-CFT-FE in conscious monkey brain. Harada N; Ohba H; Kakiuchi T; Tsukada H Synapse; 2013 Jan; 67(1):42-50. PubMed ID: 23042662 [TBL] [Abstract][Full Text] [Related]
14. In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT. Nikolaus S; Antke C; Beu M; Kley K; Larisch R; Wirrwar A; Müller HW Nucl Med Commun; 2007 Mar; 28(3):207-13. PubMed ID: 17264780 [TBL] [Abstract][Full Text] [Related]
15. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112 [TBL] [Abstract][Full Text] [Related]
16. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Kilbourn MR; Kuszpit K; Sherman P Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034 [TBL] [Abstract][Full Text] [Related]
17. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans. Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985 [TBL] [Abstract][Full Text] [Related]